Abstract 5311
Background
Nowadays, there are different guidelines in diagnostics and PET-guided treatment of lymphomas. But questions about benefits and predictive role of PET-CT in pts with early-stage Hodgkin lymphoma (HL) still remain debatable. Here we report results of Ukrainian multicenter retrospective study about the role of PET-CT in early-stage HL pts.
Methods
56 patients, with stages I-II, were registered in the study between August 2012 and Feb 2018 in 9 Ukrainian hematological centers. Metabolic PET-CT imaging was performed according to standard protocols. The threshold of positivity was set for a residual uptake higher than the liver background (Deauville score (DS) 4and 5). Patients were treated with ABVD or BEACOPPesc regimens based on risk group. The primary endpoint was event-free survival (EFS), defined as disease progression or death from HL.
Results
Median age of patients at diagnosis was 29 years (range 18-50), 16 (28,5%) male and 40 (71,5%) pts were female. Bulky disease (>10 cm in any dimension) were presented in 6/56 (10,7%) of pts, B symptoms - in 16/56 (28,5%) and extranodal disease had 4/56 (7%). Median follow-up was 24 months from diagnosis. Interim PET (PET2) was performed in 50 pts at 15.5 ±3 days (range, 5-26) after 2xABVD or 2xBEACOPP esc cycles. Interim PET-CT was assessed as DS 1-2 in 34 patients (60,7%), DS 3 in 11 (19,6%), DS 4-5 in 5 pts (8,8%). In total, disease progression was documented in 5/56 (9%). Among them, 2/5 (40%) patient were PET2-positive (PET2+) and 3/5 (60%) PET2-negative (PET2-), (p > 0.05). There were no registered deaths from the refractory disease. We did not find any significant difference between EFS rate in pts with PET2+ vs PET2- (log-rank test, p = 0.4). 47 pts have proceeded for end-of-treatment PET-CT (PET3). Results showed 3/47 pts (6,3%) were PET3+ and PET3- were 44/47 (93,7%), (p < 0,05). EFS was compared and assessed depending on DS. Achieved rate of 3-year EFS in pts with PET3 DS 1-2, DS 3 and DS 4-5 were 94,4%, 50% and 0%, respectively (p < 0.006).
Conclusions
End of treatment PET-CT plays an important role in patients with early-stage HL and could be a beneficial prognostic factor. However, there is still need for prospective confirmation of interim PET-CT as a prognostic factor.
Clinical trial identification
Legal entity responsible for the study
Tetiana Skrypets.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract